Salute e Benessere

Digital Pathology Scanner Market Size to Grow USD 1,137 Million by 2030 at a…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-19C13228/Global_Digital_Pathology_Scanner_Market_Research_Report Get Free Sample :https://reports.valuates.com/request/sample/QYRE-Auto-19C13228/Global_Digital_Pathology_Scanner_Market_Research_Report Major Factors Driving the Growth of Digital Pathology Scanner Market: The growing use of digital pathology solutions in medical and research facilities is the main factor propelling the growth of the digital...
PR Newswire
02/07/2024

2024 Rank Prizes Awarded in London for Research into Type 2 Diabetes and Retinal…

LONDON, July 2, 2024 /PRNewswire/ -- The 2024 Rank Prizes were awarded last night at a ceremony in central London. Dame Sally Davies, the UK Special Envoy on Antimicrobial Resistance, was Guest of Honour. LONDON , July 2, 2024 /PRNewswire/ -- The 2024 Rank Prizes were awarded last night at a ceremony in centralLondon. DameSally Davies, the UK Special Envoy on Antimicrobial Resistance, was Guest of Honour. Rank Prize for Nutrition ProfessorRoy Taylorand ProfessorMike...
PR Newswire
02/07/2024

Biogen Completes Acquisition of Human Immunology Biosciences

Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs).“We are very excited about the addition of felzartamab into our pipeline, further strengthening our presence in immunology with a promising late-stage therapeutic candidate being studied in multiple indications,” said Priya Singhal, M.D., M.P.H...
Nasdaq GlobeNewswire
02/07/2024

ENDOSPAN RECEIVES ADDITIONAL $25M FROM ARTIVION FOR NEXUS FDA APPROVAL PATH

More than 120,000 patients suffer thoracic aortic arch disease every year in the USA and Europe, with only about 25% diagnosed or treated. Despite significant advancements, open surgical aortic arch repair maintains high mortality and morbidity. Patients with excessive perioperative risk or anatomical factors are not indicated for surgery, yet anatomical complexity and lack of approved devices for the arch has often prohibited endovascular repair. This makes the choice of treatment difficult or…
PR Newswire
02/07/2024

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for…

Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability of AVT03 to Prolia and Xgeva, respectively, have also met their primary endpointAlvotech expects to file marketing applications for AVT03 later this year for major global marketsAlvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of...
Nasdaq GlobeNewswire
02/07/2024

Whiskey House of Kentucky Begins Production at Industry Transforming Distillery

Whiskey House was initially founded in 2022 by David Mandell, John Hargrove and Daniel Linde, the team that started and built The Bardstown Bourbon Company. As the first distillery designed from the ground up to focus solely on large-scale, flexible, contract whiskey production, Whiskey House has no brands of its own and a campus closed to the public, removing all potential conflicts of interest between the company and its customers. The team is hyper-focused on providing superior custom whiskey…
PR Newswire
02/07/2024

Pulnovo Medical Announces First Enrollment in Portugal for Global Clinical Study…

Prof. Ruben Ramos said, "PADN technology shows great potential in treating pulmonary hypertension associated with left heart disease. We are delighted to be the first in Europe to participate in this global clinical study. Our team is confident in this project and looks forward to bringing more treatment options to European pulmonary hypertension patients through this study. PADN is not only a new treatment method but also brings new hope to patients suffering from pulmonary…
PR Newswire
02/07/2024

Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and…

Mission started its multi-part, adaptive Phase I first-in-human clinical trial of MTX325 in March, beginning with a single ascending dose stage in healthy volunteers. Initial investigations of MTX325's CNS penetration ability in these healthy volunteers have yielded positive results. The multiple ascending dose stage of the study was initiated last month (June). Mission started its multi-part, adaptive Phase I first-in-human clinical trial of MTX325 in March, beginning with a single ascending...
PR Newswire
02/07/2024

Saudi Arabia to host the first-ever International Conjoined Twins Conference on…

"The United Nations General Assembly," Dr. Al Rabeeah stated, "has adopted a resolution to observe 'World Conjoined Twins Day' on 24 November each year. This is a very proud day for the Kingdom of Saudi Arabia in its ongoing humanitarian efforts to help these special children. I would like to thank the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz, and HRH Crown Prince Mohammed bin Salman, for their continued support for the Saudi Conjoined Twins Programme, which…
PR Newswire
02/07/2024

Immunovia's new lab staffed and operational after rapid implementation

All lab equipment is installed and validated. Systems for document control and quality management have been implemented. The new lab is also fully staffed following the hiring of two new scientists. All lab equipment is installed and validated. Systems for document control and quality management have been implemented. The new lab is also fully staffed following the hiring of two new scientists. The protein assays for Immunovia's next-generation test, developed in collaboration with...
PR Newswire
02/07/2024

Clarivate Identifies Six Breakthrough MedTech Trends in 2024 Set to Unlock New…

2024 marks a pivotal year for the MedTech sector following the impact of COVID-19 with significant advancements in technologies like pulsed-field ablation and ongoing growth in areas such as diabetes care and surgical robotics, as detailed in this year's Medical Technologies to Watch 2024 report. However, these innovations are directly affected by external factors such as economic uncertainty and macroeconomic trends. Industry leaders must adapt to these dynamics to navigate challenges and…
PR Newswire
02/07/2024

Preliminary revenue figures for the 2023/24 financial year

ANNOUNCEMENT NO. 270 2 July 2024 Preliminary revenue figures for the 2023/24 financial yearIn the fourth quarter of the 2023/24 financial year, ChemoMetec's revenue was DKK 109.2 million, corresponding to a growth of 13.5% from the year-earlier period.The revenue for the 2023/24 financial year was DKK 407.4 million against DKK 442.3 million the previous year, corresponding to a decrease of 7.9%. The revenue in 2023/24 is thus in line with the latest disclosed guidance for the...
Nasdaq GlobeNewswire
02/07/2024

Sobi initiates rolling biologics license application to FDA for SEL-212 for the…

"We are very pleased to initiate the rolling submission of the BLA for SEL-212, bringing Sobi one step closer to providing a potential new, effective treatment option for patients with chronic refractory gout," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs, and Chief Medical Officer at Sobi. "The Fast Track designation confirms the previously released SEL-212 phase 3 clinical data, highlighting the significant need for innovative therapies in…
PR Newswire
02/07/2024

Menarini's cell based non-invasive prenatal technology demonstrates high…

This large study, which enrolled over 1,000 women, was centered on isolating individual fetal (trophoblast) cells from maternal blood and analyzing them for both common trisomic conditions and genome-wide microdeletions and microduplications, called pathogenic copy number variants (pCNVs), that account for significant perinatal morbidity and mortality. The results presented showed that MSB's fetal cell based NIPT could deliver information beyond core "common" trisomies detected by…
PR Newswire
02/07/2024

Casino Group: Store disposals to Groupement Les Mousquetaires and Auchan Retail…

Store disposals to GroupementLes Mousquetaires and Auchan Retail France Paris, 2 July 2024Casino Group announces the sale of 66 stores 1following the agreements reached on 24 January 2024, with Groupement Les Mousquetaires and Auchan Retail France 2. This transaction is based on an enterprise value of the stores sold of 213 million euros.It is reminded that Groupement Les Mousquetaires and Auchan Retail France have undertaken to:take over all the employment contracts of...
Nasdaq GlobeNewswire
02/07/2024

Ipsen expands collaboration and license agreement for development of Cabometyx®…

Decision adds to existing collaboration agreement with Exelixis, permitting Ipsen to seek potential marketing authorizations for Cabometyx ®(cabozantinib) in advanced pancreatic and extra pancreatic neuroendocrine tumors outside of the U.S. and JapanAgreement based on CABINET Phase III trial, led by the Alliance for Clinical Trials in Oncology, which demonstrated improvements in progression-free survival for Cabometyx versus placebo 1 Ipsen has engaged with...
Nasdaq GlobeNewswire
02/07/2024

Medsenic, BioSenic's subsidiary, signed a new set of licensing and…

PRESS RELEASE – PRIVILEGED INFORMATION The adapted supply and commercialization conditions to better achieve the development of the first oral formulation of arsenic trioxide for the treatment of cGvHD should provide the best chances for final market access.Mont-Saint-Guibert, Belgium, July 2, 2024, 7.00am CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary...
Nasdaq GlobeNewswire
02/07/2024

Alvotech Issues New Shares to Holders of Convertible Bonds

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20, 2022, with maturity on December 20, 2025 (the “Convertible Bonds”).Today, Alvotech issued 22,073,578 new ordinary shares in exchange for Convertible Bonds, at the fixed price of US$10.00 per share. The majority...
Nasdaq GlobeNewswire
01/07/2024

Oncolytic Viruses: Unlocking a New Era in Cancer Immunotherapy | DelveInsight

Among the selected cancers, bladder cancer accounted for the maximum cases as compared to other selected indications in 2023 among the 7MM. As per the DelveInsight assessment, in 2023, the total incident cases of melanoma, non-melanoma skin cancer, pancreatic cancer, renal cell carcinoma, prostate cancer, brain cancer, bladder cancer, and ovarian cancer combined in the United States were 1.1 million. Among the selected cancers, bladder cancer accounted for the maximum cases as compared to…
PR Newswire
01/07/2024

/DISREGARD RELEASE: XRP Healthcare/

PR Newswire
01/07/2024

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment...
Nasdaq GlobeNewswire
01/07/2024

Pain Cloud® Launch: A Collaboration between EptivA and Infopoly Ltd., creating…

Addressing this situation, the first precision analgesics company, EptivA Therapeutics, partnering with digital technology experts Infopoly Ltd., has developed Pain Cloud®. Addressing this situation, the first precision analgesics company,EptivA Therapeutics, partnering with digital technology experts Infopoly Ltd., has developedPain Cloud®. Pain Cloud is an in-silico method, based on network biology principles, linking open access 'large-data' for unbiased 'omic' enrichment withPain...
PR Newswire
01/07/2024

Anbogen Therapeutics Announces Completion of A+ Round Financing to Advance…

Given these promising results, Anbogen decided to proceed with the A+ round of financing to secure the necessary funds for ABT-301's clinical trial, without impacting the ongoing Phase II development of ABT-101. Given these promising results, Anbogen decided to proceed with the A+ round of financing to secure the necessary funds for ABT-301's clinical trial, without impacting the ongoing Phase II development of ABT-101. Leveraging ABT-301's compelling immunomodulatory and synergistic...
PR Newswire
01/07/2024

/DISREGARD RELEASE: XRP Healthcare/

PR Newswire
01/07/2024
Altri  Comunicati